- $231.78m
- $106.61m
Palisade surges on worldwide licensing deal with Giiant Pharma
Palisade Bio Inc reports results for the quarter ended in June - Earnings Summary
Palisade Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Heritage Insurance, Mirati
U.S. STOCKS ON THE MOVE-Marqeta, Natgas firms, Bumble
Brief: Palisade Bio Announces Topline Results From U.S. Phase 2 Profile Study Evaluating LB1148 For Post-Surgical Abdominal Adhesions
Palisade slumps as lead drug candidate fails in mid-stage trial
Brief: Palisade Bio Announces Completion Of Enrollment In LB1148 Dose Optimization Study
Brief: Palisade Bio Promotes J.D. Finley To Chief Executive Officer
Brief: Palisade Bio's LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
Palisade Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Palisade Bio Reports First Quarter 2023 Financial Results
Palisade Bio Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: Palisade Bio Receives Canadian Patent Covering Composition Of Lead Program In Development, LB1148
Brief: Palisade Bio Announces Enrollment Of First Patient In Newsoara Phase 3 Clinical Trial Evaluating Lb1148
Brief: Palisade Bio Reports Year End 2022 Financial Results And Provides Corporate Update
Palisade Bio Inc reports results for the quarter ended in December - Earnings Summary
Palisade Bio Inc expected to post a loss of $2.43 a share - Earnings Preview
Brief: Palisade Bio Promotes Robert McRae To Chief Operating Officer